Jan M Middeke
Overview
Explore the profile of Jan M Middeke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
2.
Unglaub J, Unglaub J, Schlenk R, Middeke J, Middeke J, Krause S, et al.
Blood Adv
. 2024 Sep;
9(2):375-385.
PMID: 39293081
The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing...
3.
Heidenreich F, Falk B, Baldauf H, Massalski C, Schafer G, Rucker-Braun E, et al.
Blood Adv
. 2023 Jan;
7(13):2994-3004.
PMID: 36689727
Immunogenetic association studies may give rise to new hypotheses on the immune surveillance of cancer. We hypothesized that certain combinations of killer immunoglobulin-like receptor (KIR) and HLA genotypes may enhance...
4.
Kunadt D, Stasik S, Metzeler K, Rollig C, Schliemann C, Greif P, et al.
J Hematol Oncol
. 2022 Sep;
15(1):126.
PMID: 36064577
Background: The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML...
5.
Stasik S, Kramer M, Zukunft S, Rollig C, Baldus C, Platzbecker U, et al.
Front Oncol
. 2022 Apr;
12:862991.
PMID: 35387132
-ITD mutations are common druggable alterations in patients with acute myeloid leukemia (AML) and associated with poor prognosis. Beside typical ITD mutations, point mutations and deletions in the juxtamembrane domain...
6.
Stasik S, Burkhard-Meier C, Kramer M, Middeke J, Oelschlaegel U, Sockel K, et al.
Blood Adv
. 2022 Mar;
6(11):3294-3303.
PMID: 35320339
Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques...
7.
Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kruger T, et al.
Blood Adv
. 2022 Jan;
6(6):1941-1946.
PMID: 35008107
Inflammation plays an important role in chimeric antigen receptor (CAR) T-cell therapy, especially in the pathophysiology of cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Clonal hematopoiesis of...
8.
Middeke J, Metzeler K, Rollig C, Kramer M, Eckardt J, Stasik S, et al.
Blood Adv
. 2021 Nov;
6(5):1394-1405.
PMID: 34794176
Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most frequent alterations in acute myeloid leukemia (AML) and can be found in ∼20% of patients at diagnosis....
9.
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Stasik S, Eckardt J, Kramer M, Rollig C, Kramer A, Scholl S, et al.
Blood Adv
. 2021 Aug;
5(17):3279-3289.
PMID: 34459887
The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for...
10.
Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination - A Case Report
Koch M, Fuld S, Middeke J, Fantana J, von Bonin S, Beyer-Westendorf J
TH Open
. 2021 Aug;
5(3):e315-e318.
PMID: 34377889
Novel mRNA and vector-based covid-19 vaccinations have shown high efficacy in preventing symptomatic COVID-19 infections. Compared with the number of performed vaccinations, rates of severe side effects seem low. Rare...